{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:57:39Z","timestamp":1784397459207,"version":"3.55.0"},"reference-count":70,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National University of Medical Sciences","award":["02\/ORIC\/IRF-22001"],"award-info":[{"award-number":["02\/ORIC\/IRF-22001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Urothelial carcinoma (UC) presents with clinically heterogeneous disease. There is an emerging need to explore the prognosis of non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). Therefore, we aimed to explore the prognostic value of FGFR3 and TP53 mutations and protein expression and to investigate the diagnostic utility of urine cytology and Xpert bladder cancer monitor (BCM) assay in UC. Materials and Methods: A prospective cross-sectional study was conducted in a cohort of 73 Pakistani patients. Cystoscopy, biopsy, tissue diagnosis, UC grade, and stage followed by immunohistochemistry (IHC) and genotyping were recorded. Voided urine samples were also collected for urine cytology and Xpert BCM. Statistical analysis was performed using SPSS version 26.0. A p-value \u2264 0.05 was considered statistically significant. Results: In our selected patients, the majority were males who had smoking history and the common symptom was hematuria. Our findings suggest FGFR3 IHC expression is strongly linked to low-grade NMBIC (p \u2264 0.01). p53 IHC expression supports the findings of the UC grade (p \u2264 0.01). A highly significant association (p &lt; 0.001) was observed between FGFR3 protein expression and underlying mutations. Pro72Arg polymorphism (p = 0.04) was found to be significantly correlated with p53 IHC findings. While comparing cystoscopy with cytology and Xpert BCM, the sensitivity was found to be 85.7% and 58.5%, respectively. Conclusions: The integrated approach of IHC with genotyping could improve risk stratification and guide personalized management strategies. Moreover, as cytology is less sensitive to diagnose UC, especially low-grade tumours, Xpert BCM can be used as a promising diagnostic test for both primary and recurrent BC settings.<\/jats:p>","DOI":"10.3390\/jcm14238526","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:20:29Z","timestamp":1765210829000},"page":"8526","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Diagnostic and Prognostic Implications of FGFR3, TP53 Mutation and Urinary Biomarkers in Urothelial Carcinoma in Pakistani Cohort"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6795-631X","authenticated-orcid":false,"given":"Muhammad","family":"Asif","sequence":"first","affiliation":[{"name":"Department of Histopathology, Armed Forces Institute of Pathology, National University of Medical Sciences, Rawalpindi 46000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4831-1791","authenticated-orcid":false,"given":"Faiza Abdul","family":"Rashid","sequence":"additional","affiliation":[{"name":"Department of Biology, Faculty of Sciences, Allama Iqbal Open University, Islamabad 44000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima Shakil","family":"Malik","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Institute, Baylors College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilshad Ahmed","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Pathology, National University of Medical Sciences, Rawalpindi 46000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9904-8570","authenticated-orcid":false,"given":"Muhammad Tanveer","family":"Sajid","sequence":"additional","affiliation":[{"name":"Armed Forces Institute of Urology, National University of Medical Sciences, Rawalpindi 46000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Gul","sequence":"additional","affiliation":[{"name":"Precisionsmedicinskt Laboratorium, Universitetssjukhuset, 58185 Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6757-9786","authenticated-orcid":false,"given":"Muhammad Tahir","family":"Khadim","sequence":"additional","affiliation":[{"name":"Department of Pathology, National University of Medical Sciences, Rawalpindi 46000, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"ref_1","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med. Sci."},{"key":"ref_2","first-page":"625","article-title":"National cancer registry of Pakistan: First comprehensive report of cancer statistics 2015-2019","volume":"33","author":"Ikram","year":"2023","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13011-025-00658-6","article-title":"Smoking and bladder cancer: Insights into pathogenesis and public health implications from a bibliometric analysis (1999\u20132023)","volume":"20","author":"Wang","year":"2025","journal-title":"Subst. Abus. Treat. Prev. Policy"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1021\/acs.chemrestox.2c00153","article-title":"DNA damage and oxidative stress of tobacco smoke condensate in human bladder epithelial cells","volume":"35","author":"Bellamri","year":"2022","journal-title":"Chem. Res. Toxicol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clgc.2022.08.009","article-title":"Incidence of germline variants in familial bladder cancer and among patients with cancer predisposition syndromes","volume":"20","author":"Mossanen","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_6","first-page":"e1130","article-title":"Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients","volume":"1","author":"Ahmad","year":"2018","journal-title":"Cancer Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102530","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: Treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100641","DOI":"10.1016\/j.esmoop.2022.100641","article-title":"Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations","volume":"7","author":"Murugesan","year":"2022","journal-title":"ESMO Open"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e8261","DOI":"10.7717\/peerj.8261","article-title":"Significance of TP53 mutation in bladder cancer disease progression and drug selection","volume":"7","author":"Wu","year":"2019","journal-title":"PeerJ"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wu, X., Lv, D., Cai, C., Zhao, Z., Wang, M., Chen, W., and Liu, Y. (2020). A TP53-associated immune prognostic signature for the prediction of overall survival and therapeutic responses in muscle-invasive bladder cancer. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.590618"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13000-017-0605-8","article-title":"TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer","volume":"12","author":"Zhang","year":"2017","journal-title":"Diagn. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: From molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: Genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Benjamin, D.J., and Hsu, R. (2023). Treatment approaches for FGFR-altered urothelial carcinoma: Targeted therapies and immunotherapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1258388"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zhu, K.-L., Su, F., Yang, J.-R., Xiao, R.-W., Wu, R.-Y., Cao, M.-Y., Ling, X.-L., and Zhang, T. (2024). TP53 to mediate immune escape in tumor microenvironment: An overview of the research progress. Mol. Biol. Rep., 51.","DOI":"10.1007\/s11033-023-09097-7"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/s41416-022-01971-8","article-title":"Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246","volume":"127","author":"Zhou","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: Mechanisms, structures and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_19","first-page":"7","article-title":"FDA grants breakthrough device designation to urine test for bladder cancer detection","volume":"53","author":"Clarke","year":"2025","journal-title":"Urol. Times"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kavcic, N., Peric, I., Zagorac, A., and Kokalj Vokac, N. (2022). Clinical Evaluation of Two Non-invasive Genetic Tests for Detection and Monitoring of Urothelial Carcinoma: Validation of UroVysion and xpert bladder Cancer detection test. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.839598"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.juro.2017.09.141","article-title":"Development of a 90-minute integrated noninvasive urinary assay for bladder cancer detection","volume":"199","author":"Wallace","year":"2018","journal-title":"J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.eururo.2018.11.055","article-title":"Prospective validation of an mRNA-based urine test for surveillance of patients with bladder cancer","volume":"75","author":"Hiar","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_23","first-page":"1020","article-title":"Bladder Cancer in Pakistan Challenges in Early Diagnosis and Multidisciplinary Management","volume":"31","author":"Waqar","year":"2024","journal-title":"J. Popul. Ther. Clin. Pharmacol."},{"key":"ref_24","first-page":"236","article-title":"Non-occupational risk factors of urinary bladder cancer in Faisalabad and Lahore, Pakistan","volume":"62","author":"Ahmad","year":"2012","journal-title":"JPMA-J. Pak. Med. Assoc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.47391\/JPMA.9546","article-title":"A histopathological and epidemiological study of urothelial carcinoma at a tertiary care centre in Peshawar, Pakistan","volume":"74","author":"Saeed","year":"2024","journal-title":"JPMA J. Pak. Med. Assoc."},{"key":"ref_26","unstructured":"EAU (2025, February 13). EAU Guidelines on Non-Muscle-Invasive Bladder Cancer (TaT1 and Carcinoma In Situ). Available online: https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer."},{"key":"ref_27","unstructured":"National Comprehensive Cancer Network (2025). NCCN Guidelines for Patients: Bladder Cancer, National Comprehensive Cancer Network."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/PAP.0000000000000118","article-title":"The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology","volume":"23","author":"Barkan","year":"2016","journal-title":"Adv. Anat. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.18231\/j.ijpo.2021.012","article-title":"A histopathological study of urinary bladder neoplasms","volume":"8","author":"Makwana","year":"2021","journal-title":"Indian J. Pathol. Oncol."},{"key":"ref_30","unstructured":"Day, C.E. (2014). Tissue Processing and Hematoxylin and Eosin Staining. Histopathology: Methods and Protocols, Springer."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_32","unstructured":"Suvarna, S.K., Layton, C., and Bancroft, J.D. (2013). 10\u2014The hematoxylins and eosin. Bancroft\u2019s Theory and Practice of Histological Techniques, Churchill Livingstone. [7th ed.]."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.currproblcancer.2018.08.001","article-title":"Expressional analysis of MLH1 and MSH2 in breast cancer","volume":"43","author":"Malik","year":"2019","journal-title":"Curr. Probl. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejmhg.2016.03.001","article-title":"Genotypes of GSTM1 and GSTT1: Useful determinants for clinical outcome of bladder cancer in Pakistani population","volume":"18","author":"Malik","year":"2017","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00345-019-03002-3","article-title":"Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): Results from the Bladder Cancer Italian Active Surveillance (BIAS) project","volume":"38","author":"Hurle","year":"2020","journal-title":"World J. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Kacew, A., and Sweis, R.F. (2020). FGFR3 alterations in the era of immunotherapy for urothelial bladder cancer. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.575258"},{"key":"ref_37","unstructured":"Sites, A. (2014). SEER Cancer Statistics Review 1975\u20132011, National Cancer Institute."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s13193-023-01861-2","article-title":"Clinico-demographic Profile of Carcinoma Urinary Bladder\u20145-Year Experience from a Tertiary Care Centre of Eastern India","volume":"15","author":"Biswas","year":"2024","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3233\/BLC-211583","article-title":"Association between Smoking and Overall and Specific Mortality in Patients with Bladder Cancer: A Population-based Study","volume":"8","author":"Ho","year":"2022","journal-title":"Bladder Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e13981","DOI":"10.14814\/phy2.13981","article-title":"Cigarette smoking promotes bladder cancer via increased platelet-activating factor","volume":"7","author":"Kispert","year":"2019","journal-title":"Physiol. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"FSO394","DOI":"10.2144\/fsoa-2019-0017","article-title":"The effects of cigarette smoking extracts on cell cycle and tumor spread: Novel evidence","volume":"5","author":"Pezzuto","year":"2019","journal-title":"Future Sci. OA"},{"key":"ref_42","first-page":"1691","article-title":"Carcinoma of urinary bladder; Extent of carcinoma of urinary bladder on first presentation and its impact on management","volume":"24","author":"Hussain","year":"2017","journal-title":"Prof. Med. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1586\/14737140.8.7.1111","article-title":"Bladder tumor markers: From hematuria to molecular diagnostics\u2013where do we stand?","volume":"8","author":"Shirodkar","year":"2008","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Jakus, D., \u0160oli\u0107, I., Juri\u0107, I., Borovac, J.A., and \u0160itum, M. (2023). The Impact of the Initial Clinical Presentation of Bladder Cancer on Histopathological and Morphological Tumor Characteristics. J. Clin. Med., 12.","DOI":"10.3390\/jcm12134259"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.30699\/ijp.14.2.148","article-title":"Role of FGFR3 in Urothelial Carcinoma","volume":"14","author":"Akanksha","year":"2019","journal-title":"Iran. J. Pathol."},{"key":"ref_46","first-page":"1","article-title":"Prognostic value of FGFR3 expression in Urinary bladder cancer","volume":"17","author":"Abdiwi","year":"2023","journal-title":"Onkol. I Radioter."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"141","DOI":"10.32421\/juri.v27i2.551","article-title":"The Immunoexpression Profile of FGFR3 and P53 in Punlmp and Urothelial Bladder Carcinoma at Hasan Sadikin General Hospital","volume":"27","author":"Suryanti","year":"2020","journal-title":"Indones. J. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"156028","DOI":"10.1016\/j.prp.2025.156028","article-title":"FGFR3 Immunohistochemistry as a Surrogate Biomarker for FGFR3 Alterations in Urothelial Carcinoma","volume":"271","author":"Mercader","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"ref_49","first-page":"301.e17","article-title":"Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project","volume":"39","author":"Wang","year":"2021","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/his.12473","article-title":"Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer","volume":"66","author":"Fischbach","year":"2015","journal-title":"Histopathology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1038\/s41467-019-10489-2","article-title":"A pan-cancer analysis of synonymous mutations","volume":"10","author":"Sharma","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/djac090","article-title":"Synonymous variants: Necessary nuance in our understanding of cancer drivers and treatment outcomes","volume":"114","author":"Kaissarian","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/cam4.262","article-title":"FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder","volume":"3","author":"Guancial","year":"2014","journal-title":"Cancer Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2005.05.1771","article-title":"Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas","volume":"24","author":"Lloreta","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.47723\/cp575x89","article-title":"Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer: A Marker for Early-Stage Diagnosis","volume":"21","author":"Elessawy","year":"2025","journal-title":"AL-Kindy Coll. Med. J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3233\/BLC-200373","article-title":"FGFR3\u2013a central player in bladder cancer pathogenesis?","volume":"6","author":"Knowles","year":"2020","journal-title":"Bladder Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/1535-7163.MCT-12-1150","article-title":"Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer","volume":"12","author":"Gust","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/modpathol.2013.135","article-title":"Advanced urothelial carcinoma: Next-generation sequencing reveals diverse genomic alterations and targets of therapy","volume":"27","author":"Ross","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2023.41.6_suppl.504","article-title":"Phase 2 study of the efficacy and safety of erdafitinib in patients (pts) with intermediate-risk non\u2013muscle-invasive bladder cancer (IR-NMIBC) with FGFR3\/2 alterations (alt) in THOR-2: Cohort 3 interim analysis","volume":"41","author":"Daneshmand","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Neuzillet, Y., Paoletti, X., Ouerhani, S., Mongiat-Artus, P., Soliman, H., de The, H., Sibony, M., Denoux, Y., Molinie, V., and Herault, A. (2012). A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048993"},{"key":"ref_61","first-page":"e65816","article-title":"Evaluation of fibroblast growth factor receptor 3 (FGFR3) and tumor protein P53 (TP53) as independent prognostic biomarkers in high-grade non-muscle invasive bladder cancer","volume":"16","author":"Kumar","year":"2024","journal-title":"Cureus"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"64910","DOI":"10.18632\/oncotarget.11912","article-title":"Immunohistochemical correlates of TP53 somatic mutations in cancer","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"ref_63","first-page":"77.e9","article-title":"Prospective validation of clinical usefulness of a novel mRNA-based urine test (Xpert\u00ae Bladder Cancer Monitor) for surveillance in non muscle invasive bladder cancer","volume":"39","author":"Elsawy","year":"2021","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_64","unstructured":"Abuhasanein, S. (2024). Optimizing the Early Diagnosis Process of Urinary Bladder Cancer. On Standardized Care Pathway, Computed Tomography, Artificial Intelligence, and a Newly Developed Urine-Based Cancer Marker. [Ph.D. Thesis, Gothenburg University]."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/bju.14459","article-title":"Does urinary cytology have a role in haematuria investigations?","volume":"123","author":"Tan","year":"2019","journal-title":"BJU Int."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4274\/uob.galenos.2024.2024.3.3","article-title":"Contemporary Role of Urine Cytology in Bladder Cancer","volume":"23","author":"Kars","year":"2024","journal-title":"Bull. Urooncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/iju.15338","article-title":"Urinary markers for bladder cancer diagnosis: A review of current status and future challenges","volume":"31","author":"Tomiyama","year":"2024","journal-title":"Int. J. Urol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.euros.2024.09.001","article-title":"Xpert Bladder Cancer Detection in Emergency Setting Assessment (XESA Project): A Prospective, Single-centre Trial","volume":"71","author":"Sordelli","year":"2025","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12943-024-02140-6","article-title":"Artificial intelligence alphafold model for molecular biology and drug discovery: A machine-learning-driven informatics investigation","volume":"23","author":"Guo","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Guo, S.-B., Liu, D.-Y., Fang, X.-J., Meng, Y., Zhou, Z.-Z., Li, J., Li, M., Luo, L.-L., Li, H.-L., and Cai, X.-Y. (2025). Current concerns and future directions of large language model chatGPT in medicine: A machine-learning-driven global-scale bibliometric analysis. Int. J. Surg.","DOI":"10.1097\/JS9.0000000000003668"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/23\/8526\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:31:58Z","timestamp":1765211518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/23\/8526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":70,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14238526"],"URL":"https:\/\/doi.org\/10.3390\/jcm14238526","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}